|Day Low/High||38.19 / 38.53|
|52 Wk Low/High||32.69 / 41.77|
AstraZeneca, together with Acerta Pharma, its hematology research and development center of excellence, and MedImmune, its global biologics research and development arm, will present 27 abstracts, including six oral presentations, at the 2018 American...
AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA (dapagliflozin).
AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular (CV) outcomes trial (CVOT) DECLARE (Dapagliflozin Effect on Cardiovascular Events)-TIMI 58, the broadest SGLT2...
AstraZeneca will present new research spanning the Company's Cardiovascular, Renal and Metabolism (CVRM) therapy area at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in San Diego, US, October 23-28, 2018.
AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of IMFINZI ® (durvalumab) during the Presidential Symposium of the IASLC 19th World Conference on...
AstraZeneca today announced the first shipment of FLUMIST ® QUADRIVALENT (Influenza Vaccine Live, Intranasal) doses in the US for the 2018-2019 influenza season.
AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA ® (dapagliflozin), the broadest SGLT-2 inhibitor CVOT conducted to date.
AstraZeneca today announced results from the Phase III extension BORA trial evaluating the long-term safety and efficacy of FASENRA™ (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who had previously completed...
Both biotech stocks are at or near 52-week lows, but don't deserve to be.
AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration (FDA) has approved LUMOXITI™ (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or...
Designation Supported by Phase 2b PATHWAY Data That Demonstrated Tezepelumab Significantly Reduced Asthma Exacerbations Compared to Placebo in Severe Asthma Patients
This at-the-money, long put shooter is a high risk trade, so use discretionary capital.
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
Biogen delivered promising results on a new Alzheimer's disease treatment. And investors rewarded the company accordingly.
The company's drug showed promising results versus a placebo in a Phase 2 trial.
AstraZeneca and Merck & Co., Inc.
AstraZeneca (NYSE: AZN) presented key data on the use of FARXIGA ® (dapagliflozin) in diverse patient populations with type 2 and type 1 diabetes (T2D, T1D) at the American Diabetes Association (ADA) 78th Scientific Sessions this week in Orlando, FL, June...
AstraZeneca and its global biologics research and development arm, MedImmune, will present 45 abstracts including seven late-breaking data disclosures from the Company's Cardiovascular (CV), Renal and Metabolism (CVRM) therapy area at the American...
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
The biopharmaceutical companies saw their stocks drop amid fallout of failed Alzheimer's drug trials.
Stocks finished mixed on Tuesday, following the summit between Donald Trump and North Korean leader Kim Jong Un and as Wall Street turns its attention the start of the Federal Reserve's two-day meeting.
Jim discusses our Salesforce buy, Eli Lilly, UnitedHealth and Cimarex and also answers a club member's question!
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.